Cerity Partners LLC Sells 5,426 Shares of Moderna, Inc. (NASDAQ:MRNA)

Cerity Partners LLC reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 39.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,343 shares of the company’s stock after selling 5,426 shares during the quarter. Cerity Partners LLC’s holdings in Moderna were worth $347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC boosted its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter valued at approximately $37,000. Crowley Wealth Management Inc. bought a new position in shares of Moderna during the 4th quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

MRNA stock opened at $26.52 on Thursday. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The business has a fifty day moving average price of $30.48 and a 200-day moving average price of $39.07. The stock has a market capitalization of $10.25 billion, a P/E ratio of -2.86 and a beta of 2.23.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of analyst reports. Berenberg Bank increased their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Leerink Partners cut their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. JPMorgan Chase & Co. reduced their target price on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Friday, March 21st. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.